Differentiation syndrome in patients with acute promyelocytic leukemia

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 1, 2012, Pages 109-114

  Rogers, Jane E ^a   Yang, Daisy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

acute promyelocytic leukemia; Differentiation syndrome

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; PREDNISONE; RETINOIC ACID;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CARCINOGENESIS; CARDIOPULMONARY INSUFFICIENCY; CORTICOSTEROID THERAPY; DIFFERENTIATION SYNDROME; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; DYSPNEA; FEVER; HUMAN; HYPERLEUKOCYTOSIS; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUNG EDEMA; MEDLINE; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RESPIRATORY DISTRESS; RETINOIC ACID SYNDROME; REVIEW; RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS; ARSENICALS; GLUCOCORTICOIDS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTE COUNT; OXIDES; RISK FACTORS; SYNDROME; TIME FACTORS; TRETINOIN;

EID: 84857988828     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155211399163     Document Type: Review

References (29)

1. Patatanian E, Thompson DF. Retinoic acid syndrome: a review. J Clin Pharm Ther. 2008 ; 33 (4). 331-338
2. Larson RS, Tallman MS. Retinoic acid syndrome: manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol. 2003 ; 16 (3). 453-461
3. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendation from an expert panel on behalf of the European LeukemiaNet. Blood. 2009 ; 113: 1875-1891
4. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008 ; 111 (5). 2505-2515
5. Acute Myeloid Leukemia NCCN Clinical Practice Guidelines in Oncology (Version 2.2011). © 2010 National Comprehensive Cancer Network, Inc. http://www.nccn.org (accessed December 5, 2010).
6. Licht JD. Acute promyelocytic leukemia-weapons of mass differentiation. N Engl J Med. 2009 ; 360 (9). 928-930
7. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood. 2009 ; 114 (25). 5126-5135
8. De la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008 ; 111 (7). 3395-3402
9. Lo-Coco F, Ammatuna E, Montesinos P, Sanz MA. Acute promyelocytic leukemia: recent advances in diagnosis and management. Semin Oncol. 2008 ; 35 (4). 401-409
10. Luesink M, Pennings JL, Wissink WM, et al. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood. 2009 ; 114: 5512-5521
11. Camacho LH, Soignet SL, Chanel S, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol. 2000 ; 18 (13). 2620-2625 (Pubitemid 30432530)
12. Emadi A, Gore SD. Arsenic trioxide-an old drug rediscovered. Blood Rev. 2010 ; 24 (4-5). 191-199
13. De Botton S, Dombret H, Sanz M. Incidence, clinical features, and outcome of all-trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1998 ; 92 (8). 2712-2718 (Pubitemid 28469083)
14. De Botton S, Chevret S, Coiteux V, et al. Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. Leukemia. 2003 ; 17: 339-342 (Pubitemid 36266911)
15. Rust DM, Soignet SL. Risk/benefit profile of arsenic trioxide. Oncologist. 2001 ; 6 (Suppl 2). 29-32 (Pubitemid 32405847)
16. Gupta V, Yi QL, Brandwein J. Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL). Leuk Res. 2005 ; 29 (1). 113-114 (Pubitemid 39487918)
17. Ferrara F. Acute promyelocytic leukemia: what are the treatment options?. Expert Opin Pharmacother. 2010 ; 11 (4). 587-596
18. Roche Laboratories, Inc. Vesanoid® (tretinoin) package insert. Nutley, NJ; October 2004.
19. Cephalon, Inc. Trisenox® (arsenic trioxide) package insert. Frazer, PA; June 2010.
20. Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin MC, de The H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res. 2009 ; 15 (20). 6321-6326
21. Ninomiya M, Kiyoi H, Ito M, Hirose Y, Ito M, Naoe T. Retinoic acid syndrome in NOD/scid mice induced by an acute promyelocytic leukemia cell line. Leukemia. 2004 ; 18 (3). 442-448 (Pubitemid 38425857)
22. Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009 ; 113: 775-783
23. Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York study. Ann Intern Med. 1994 ; 120: 278-286 (Pubitemid 24050023)
24. Jeddi R, Kacem K, Ben Neji H, et al. Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia. Hematology. 2008 ; 13 (3). 142-146
25. Jeddi R, Ghedira H, Mnif S, Gouider E, Fenaux P, Meddeb B. High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res. 2010 ; 34 (4). 545-547
26. Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004 ; 103 (4). 1237-1243 (Pubitemid 38168633)
27. Kelaidi C, Chevret S, De Botton S, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol. 2009 ; 27 (16). 2668-2676
28. Tallman MS, Anderson JW, Schiffer CA, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000 ; 95 (1). 90-95 (Pubitemid 30017230)
29. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997 ; 337 (15). 1021-1028 (Pubitemid 27430519)